<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; unfettered</title>
	<atom:link href="http://www.tapanray.in/tag/unfettered/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unfettered ‘Access To Drug Innovation’ &#8211; An Oxymoron?</title>
		<link>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unfettered-access-to-drug-innovation-an-oxymoron</link>
		<comments>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/#comments</comments>
		<pubDate>Mon, 06 Sep 2021 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[customer. consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[off-patent]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[property< India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[undermining]]></category>
		<category><![CDATA[unfettered]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10582</guid>
		<description><![CDATA[The mass paranoia, as it were, over Covid pandemic has now started fading with drug regulators’ ‘emergency approval’ of several Covid -19 vaccines, and its free of cost access to all, generally in most countries. As the endgame of the pandemic, &#8230; <a href="http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
